公开(公告)号：WO2004032960A1

公开(公告)日：2004-04-22

申请号：PCT/EP2003/011164

申请日：2003-10-09

Applicant: MERCK PATENT GMBH ,  KREYSCH, Hans-Georg ,  SCHMIDT, Jürgen

Inventor： KREYSCH, Hans-Georg ,  SCHMIDT, Jürgen

IPC: A61K39/395

CPC classification number: C07K16/32 ,  A61K39/395 ,  A61K2039/505 ,  C07K16/2863 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  Y10S435/81 ,  A61K2300/00

Abstract: The invention relates to pharmaceutical compositions comprising different molecules, preferably monoclonal antibodies, each comprising epitopes that bind simultaneously to different sites within the same ErbB 1 receptor domain. The preferred antibodies according to this invention are MAb 425 and MAb 225 each in its murine, chimeric and humanized version. The invention relates to the use and methods for an improved treatment of preferably tumors by means of said compositions.

Abstract translation: 本发明涉及包含不同分子，优选单克隆抗体的药物组合物，每种分子包含与同一ErbB1受体结构域内的不同位点同时结合的表位。 根据本发明的优选抗体是其鼠，嵌合和人源化版本中的MAb 425和MAb 225。 本发明涉及通过所述组合物改进优选治疗肿瘤的用途和方法。

公开(公告)号：WO02055106A3

公开(公告)日：2003-03-06

申请号：PCT/EP0115241

申请日：2001-12-21

Applicant: MERCK PATENT GMBH ,  GOODMAN SIMON ,  KREYSCH HANS-GEORG

Inventor： GOODMAN SIMON ,  KREYSCH HANS-GEORG

IPC: A61K45/06 ,  A61K31/337 ,  A61K31/704 ,  A61K31/7064 ,  A61K31/7068 ,  A61K33/24 ,  A61K38/00 ,  A61K38/08 ,  A61K39/395 ,  A61K41/00 ,  A61K47/48 ,  A61P35/00 ,  A61P35/04 ,  A61P43/00 ,  C07K16/30

CPC classification number: C07K16/30 ,  A61K38/08 ,  A61K39/39558 ,  A61K41/0038 ,  A61K2039/505 ,  A61K2300/00

Abstract: The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of receptor tyrosine kinase antagonists/inhibitors, especially ErbB receptor antagonists, more preferably EGF receptor (Her 1) antagonists and anti-angiogenic agents, preferably integrin antagonists, optionally together with agents or therapy forms that have additive or synergistic efficacy when administered together with said combination of antagonists/inhibitors, such as chemotherapeutic agents and or radiation therapy. The therapy can result in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone.

Abstract translation: 本发明涉及用于治疗肿瘤和肿瘤转移的组合疗法，其包括施用受体酪氨酸激酶拮抗剂/抑制剂，特别是ErbB受体拮抗剂，更优选EGF受体（Her1）拮抗剂和抗血管生成剂，优选整联蛋白拮抗剂，任选地 以及当与所述拮抗剂/抑制剂如化学治疗剂和/或放射治疗的组合一起施用时具有添加或协同效力的药剂或治疗形式。 该治疗可以导致每个单独治疗剂对肿瘤细胞增殖的抑制作用的协同增加，产生比通过单独施用单独组分所发现的更有效的治疗。

公开(公告)号：WO2004032961A1

公开(公告)日：2004-04-22

申请号：PCT/EP2003/011165

申请日：2003-10-09

Applicant: MERCK PATENT GMBH ,  KREYSCH, Hans-Georg

Inventor： KREYSCH, Hans-Georg

IPC: A61K39/395

CPC classification number: C07K16/32 ,  A61K39/395 ,  A61K2039/505 ,  C07K16/2863 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  Y10S435/81 ,  A61K2300/00

Abstract: The invention relates to novel bispecific antibodies and their use in tumor therapy. The novel antibodies have the ability to bind to ErbB receptors, preferably ErbB1 receptors, which are overexpressed on many cancer tissues. Since the different specificities of the antigen-binding sites are directed to different epitopes within the binding domain of same or different ErbB receptors, these antibodies are more effective with respect to inhibition and down-regulation of the ErbB receptor and the corresponding signaling cascade.

Abstract translation: 本发明涉及新型双特异性抗体及其在肿瘤治疗中的应用。 新型抗体具有结合在许多癌组织上过表达的ErbB受体，优选ErbB1受体的能力。 由于抗原结合位点的不同特异性针对相同或不同ErbB受体的结合结构域内的不同表位，所以这些抗体在ErbB受体的抑制和下调以及相应的信号级联方面更有效。